Necrotizing Pancreatitis Clinical Trial
Official title:
Endoscopic Large Caliber Drainage vs. Complete Necrosectomy for Treatment of Walled-off Pancreatic Necrosis: A Prospective, Randomized Noninferiority Trial.
| NCT number | NCT02564965 |
| Other study ID # | 14-001390 |
| Secondary ID | |
| Status | Withdrawn |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | February 2019 |
| Est. completion date | December 2020 |
| Verified date | April 2019 |
| Source | Mayo Clinic |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to determine optimal treatment strategies for symptomatic walled-off pancreatic necrosis( WON).
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | December 2020 |
| Est. primary completion date | December 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 60 Years |
| Eligibility |
Inclusion Criteria: - Adult (> 18 yo) patients - With symptomatic walled- off pancreatic necrosis in which an endoscopic approach is appropriate based on cross-sectional imaging - Must have solid necrotic material present in their pancreatic fluid collection as determined by MRI, EUS, or direct transluminal endoscopic imaging of the collection Exclusion Criteria: - Previous intervention for pancreatic necrosis (surgical, percutaneous, or endoscopic) - Indication for emergency laparotomy (compartment syndrome, bowel ischemia, bleeding, or perforation of a GI lumen) - Uncorrectable coagulopathy. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Mayo Clinic |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Complete resolution as defined by complete radiographic resolution of the walled-off necrosis (WON) | Baseline to 4 months after initiation of endoscopic treatment | ||
| Secondary | Clinical resolution of infection as defined by complete radiographic resolution and/or symptoms of pain and gastric outlet obstruction | Baseline to 4 months after initiation of endoscopic treatment | ||
| Secondary | Symptom resolution (Visual Analogue Scale for pain, gastric outlet obstruction, and weight gain) | Baseline to 4 months after initiation of endoscopic treatment | ||
| Secondary | Decrease in incidence of adverse events | Baseline to 4 months after initiation of endoscopic treatment | ||
| Secondary | Decrease in number of hospital days during treatment course | Baseline to 4 months after initiation of endoscopic treatment | ||
| Secondary | Decrease in total costs of pancreatitis-related health care during treatment course | Baseline to 4 months after initiation of endoscopic treatment |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04986943 -
ABTHERA ADVANCE⢠Use Without Wittman Patch
|
||
| Completed |
NCT03694210 -
EndoRotor DEN (Direct Endoscopic Necrosectomy)Trial
|
N/A | |
| Completed |
NCT01815489 -
Molecular Analysis of Microbial DNA in Infected Necrotizing Pancreatitis
|
||
| Not yet recruiting |
NCT04963868 -
Timing of Transmural Stent Removal in Necrotizing Pancreatitis
|
N/A | |
| Completed |
NCT03115918 -
Pancreatic Duct Stent for Acute Necrotizing Pancreatitis
|
N/A | |
| Not yet recruiting |
NCT06380842 -
Organ Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy
|